Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 9102 results

  1. Magtrace/Sentimag MT599 (MIB263)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Signatera molecular residual disease assay (MT741)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. URO17 for testing suspected bladder cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Modified release hydrocortisone capsules for treating adrenal insufficiency in people 12 years and over [TSID12254]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Thromboaspiration for Intermediate risk Pulmonary Embolism

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Mechanical Thrombectomy for PE

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. An aortic cuff counterpulsation system for the treatment of heart failure

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation